#Coronavirus Disease Research #References (by AMEDEO, April 19 '26)

 

Ann Intern Med

1. ALBALOUL H, Nemer A, Saini N, Schuster MG, et al
   Infectious Diseases: What You May Have Missed in 2025.
   Ann Intern Med. 2026 Apr 14:e2600983. doi: 10.7326/ANNALS-26-00983.
   PubMed         Abstract available
   
   

   
   BMJ

2. DAVIES SR, Davies AL, Higgins JPT, Caldwell DM, et al
   Effectiveness of interventions to increase vaccine uptake: component network meta-analysis.
   BMJ. 2026;393:e087578.
   PubMed         Abstract available
   
   
3. PAGEL C
   The UK Covid-19 Inquiry lays bare the cost of delayed action for NHS staff.
   BMJ. 2026;393:s696.
   PubMed        
   
   

   
   Clin Infect Dis

4. THORPE A, Lee RA, Szymczak JE, Farrell MC, et al
   Comparing the Antimicrobial Resistance Crisis to the Coronavirus Disease 2019 Pandemic: A Randomized Public Health Messaging Experiment.
   Clin Infect Dis. 2026 Apr 8:ciag110. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Emerg Infect Dis

5. ISMAIL H, Perovic O, Mpembe R, Lowman W, et al
   Accelerated Increase in Candida auris Bloodstream Infections during COVID-19 Pandemic, South Africa.
   Emerg Infect Dis. 2026;32:563-572.
   PubMed         Abstract available
   
   
6. ANDRES C, Prats-Mendez I, Midgley S, Berginc N, et al
   Circulation Patterns, Genetic Diversity, and Public Health Implications of Enterovirus D68, Europe, 2014-2024.
   Emerg Infect Dis. 2026;32:491-499.
   PubMed         Abstract available
   
   

   
   Infect Control Hosp Epidemiol

7. DUROCHER F, Dufresne SF, Dufresne PJ, Marchand-Senecal X, et al
   Healthcare-associated Pneumocystis jirovecii transmission in the era of universal masking and distancing.
   Infect Control Hosp Epidemiol. 2026 Apr 13:1-6. doi: 10.1017/ice.2026.10446.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

8. NGIAM JN, Yap AJ, Wee LE, Koh MCY, et al
   Parental Vaccination Status and Other Socioeconomic Determinants Shaping COVID-19 Vaccine Uptake in Children and Adolescents in Singapore.
   Int J Infect Dis. 2026 Apr 15:108686. doi: 10.1016/j.ijid.2026.108686.
   PubMed         Abstract available
   
   
9. ALI AS, Vanoli E, Smati-Lafarge M, Boudjemaa A, et al
   Computational Fluid Dynamics and Genotyping to explore Airborne Transmission of Respiratory Viruses in Hospitals.
   Int J Infect Dis. 2026 Apr 9:108697. doi: 10.1016/j.ijid.2026.108697.
   PubMed         Abstract available
   
   
10. GARDINER LE, Lozano-Rojas D, Smith N, Espley J, et al
    Investigating prognostic classifications of pre-existing multiple long-term conditions for health outcomes one-year after COVID-19 hospitalisation: a UK prospective observational study.
    Int J Infect Dis. 2026 Apr 9:108695. doi: 10.1016/j.ijid.2026.108695.
    PubMed         Abstract available
    
    

    
    Intensive Care Med

11. MYATRA SN, Nasa P, Chanchalani GP, Zimmerman JL, et al
    Gender equality and equity in intensive care: an international Delphi consensus study.
    Intensive Care Med. 2026 Apr 15. doi: 10.1007/s00134-026-08394.
    PubMed         Abstract available
    
    

    
    J Med Virol

12. MULLER V, Kolditz M, Shvachko V, Oppelt T, et al
    Effectiveness of Remdesivir on All-Cause In-Hospital Mortality in Patients With Chronic Respiratory Comorbidities Who Are Hospitalized With COVID-19 in the United States.
    J Med Virol. 2026;98:e70926.
    PubMed         Abstract available
    
    
13. CAPPARELLI E, Maggiolini D, Paschale M, Pavia C, et al
    Changes in ANA Positivity Following SARS-CoV-2 Outbreak in Lombardy Region, Italy.
    J Med Virol. 2026;98:e70927.
    PubMed         Abstract available
    
    

    
    J Virol

14. RAHEJA H, Sahu R, Ghosh T, Paul S, et al
    HuR enhances SARS-CoV-2 non-structural protein translation through the genomic 5'-UTR, by promoting polypyrimidine tract-binding protein binding.
    J Virol. 2026 Apr 16:e0027626. doi: 10.1128/jvi.00276.
    PubMed         Abstract available
    
    

    
    JAMA

15. RUBIN R
    What to Know About Cicada, or BA.3.2, the Latest SARS-CoV-2 Variant Under Monitoring.
    JAMA. 2026 Apr 17. doi: 10.1001/jama.2026.5535.
    PubMed        
    
    

    
    Life Sci

16. BARTOLOMEO CS, Lemes RMR, Morais RL, Pereria GC, et al
    Corrigendum to "SARS-CoV-2 infection and replication kinetics in different human cell types: The role of autophagy, cellular metabolism and ACE2 expression" [Life Sciences 308 (2022) 120930].
    Life Sci. 2026 Apr 9:124367. doi: 10.1016/j.lfs.2026.124367.
    PubMed        
    
    

    
    Nat Ment Health

17. HIDALGO-PADILLA L, Gogarty E, Sarkodie R, Gaughran F, et al
    Primary care consultation modality and acute mental health service use in adults.
    Nat Ment Health. 2026;4:574-581.
    PubMed         Abstract available
    
    

    
    Nature

18. STEINER C
    Almost half of traded wildlife carries disease-causing pathogens.
    Nature. 2026 Apr 9. doi: 10.1038/d41586-026-01121.
    PubMed        

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, April 19 '26)

 

Biochem Biophys Res Commun

1. CHEN M, Chen W, Jiang X, Liang S, et al
   Virtual screening targeting the conserved domain of the IAV M2 protein reveals the potential broad-spectrum anti-IAV activity of ajmaline.
   Biochem Biophys Res Commun. 2026;814:153643.
   PubMed         Abstract available
   
   

   
   BMJ

2. DAVIES SR, Davies AL, Higgins JPT, Caldwell DM, et al
   Effectiveness of interventions to increase vaccine uptake: component network meta-analysis.
   BMJ. 2026;393:e087578.
   PubMed         Abstract available
   
   

   
   Drug Saf

3. HWANG CS, Lu Z, Russo M, Zakoul H, et al
   Physician Awareness of FDA's Relaxation of REMS-Required Laboratory Testing Requirements and Changes in Prescribing Practices During the COVID-19 Pandemic.
   Drug Saf. 2026;49:519-528.
   PubMed         Abstract available
   
   
4. COATES MM, Rowe SL, Sullivan SG, Munoz FM, et al
   Assessing the Use of Medical Insurance Claims and Electronic Health Records to Measure COVID-19 Vaccination During Pregnancy.
   Drug Saf. 2026;49:567-580.
   PubMed         Abstract available
   
   
5. RACHWAL O, Gutierrez-Lobon M, Cueto NS, Ventura AN, et al
   Evaluating COVID-19 Vaccine Masking and Unmasking Methods in Two National Pharmacovigilance Databases.
   Drug Saf. 2026;49:581-590.
   PubMed         Abstract available
   
   
6. JAJOU R, van Puijenbroek E, Overbeek J, Hek K, et al
   GP Consultations for Herpes Zoster After COVID-19 Vaccination: A Self-Controlled Cohort Study Based on Electronic Health Record Data from the Netherlands.
   Drug Saf. 2026;49:529-539.
   PubMed         Abstract available
   
   

   
   Epidemiol Infect

7. GONZALES BE, Ochoa TJ, van der Sande MAB
   Inequalities in complete pneumococcal vaccination among Peruvian children before and after the COVID-19 pandemic: An evaluation using demographic and health surveys from 2018 to 2023.
   Epidemiol Infect. 2026;154:e49.
   PubMed         Abstract available
   
   
8. KIMURA M, Asai Y, Tsuzuki S, Shimizu Y, et al
   Effectiveness of voluntary PCR testing against COVID-19 spread in remote Japanese islands.
   Epidemiol Infect. 2026;154:e48.
   PubMed         Abstract available
   
   

   
   J Virol Methods

9. ASGHARI M, Golalipour M, Memarian A, Farazmandfar T, et al
   Presentation of multiple copies of a non-dominant surface epitope by circular RNA effectively induce an immune response against SARS-CoV-2.
   J Virol Methods. 2026;343:115378.
   PubMed         Abstract available
   
   
10. CHIBA S
    Therapeutic mechanisms of early oseltamivir administration in the management of mild COVID-19 through the sympathetic nervous system: A scoping review.
    J Virol Methods. 2026;343:115386.
    PubMed         Abstract available
    
    

    
    Lancet

11. JOHANSEN ND, Seco JP, Martinon-Torres F, Biering-Sorensen T, et al
    Unclear benefits of higher doses of influenza vaccine - Authors' reply.
    Lancet. 2026;407:1426.
    PubMed        
    
    
12. FLAHAULT A
    Unclear benefits of higher doses of influenza vaccine.
    Lancet. 2026;407:1425-1426.
    PubMed        
    
    

    
    PLoS Biol

13. SOLA I, Zuniga S
    New transcription signals in SARS-CoV-2 reshape virus-host interactions.
    PLoS Biol. 2026;24:e3003744.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

14. JEONG YD, Hart WS, Ishikane M, Kim KS, et al
    Identifying the optimal rapid antigen test for screening and determining the end of isolation: A modeling study.
    PLoS Comput Biol. 2026;22:e1013102.
    PubMed         Abstract available
    
    
15. ANOKYE F, Li MWZ, Walker S, Hurford A, et al
    Quantifying SARS-CoV-2 Omicron variant spread and the impact of non-pharmaceutical interventions in Newfoundland and Labrador, Canada.
    PLoS Comput Biol. 2026;22:e1013562.
    PubMed         Abstract available
    
    

    
    PLoS One

16. ABDELGHANY M, Yu F, Rennard S, Gwon Y, et al
    Bayesian reanalysis of early remdesivir for the treatment of COVID-19 in outpatients with high risk of progression to severe disease.
    PLoS One. 2026;21:e0346878.
    PubMed         Abstract available
    
    
17. BERBER E, Hanley HB, Gamez BM, Ross TM, et al
    Assessment of hemagglutinin-inhibition activity following influenza vaccination during the 2022-2023, 2023-2024, and 2024-2025 seasons.
    PLoS One. 2026;21:e0347314.
    PubMed         Abstract available
    
    
18. MURALIDHAR K, Ngaybe MGB, Pope B, Nanjaiah S, et al
    Behavioural and Social Drivers (BeSD) of COVID-19 vaccination for children: A cross-sectional study of parental vaccine confidence and intent in Mysore, India.
    PLoS One. 2026;21:e0316877.
    PubMed         Abstract available
    
    
19. BHUPATHI M, Hegde S, Molloy JC, Devarapu GCR, et al
    MobileLAMP: A low-cost, portable incubation device for isothermal nucleic acid amplification.
    PLoS One. 2026;21:e0346874.
    PubMed         Abstract available
    
    
20. SHIMAZU Y, Isoda N, Hiono T, Hew YL, et al
    Evaluation of therapeutic efficacy of baloxavir marboxil against high pathogenicity avian influenza virus infection in duck model.
    PLoS One. 2026;21:e0347205.
    PubMed         Abstract available
    
    
21. GANGAT R, Ngah V, Tawonga R, Blanford JI, et al
    Spatial and temporal patterns of SARS-CoV-2 infection in uMgungundlovu, KwaZulu-Natal, South Africa.
    PLoS One. 2026;21:e0317648.
    PubMed         Abstract available
    
    
22. VAN DUINKERKEN A, van der Velden PG, Duckers MLA, Baliatsas C, et al
    Revisiting the exposure criterion for PTSD: Using the COVID-19 pandemic as an opportunity to assess measurement invariance of PTSD symptoms across event types.
    PLoS One. 2026;21:e0347315.
    PubMed         Abstract available
    
    
23. KITTUR ME, Jones BDM, Imran S, Wang W, et al
    Impact of the COVID-19 pandemic on adults accessing specialist psychiatric care: A cross-sectional Canadian analysis.
    PLoS One. 2026;21:e0346913.
    PubMed         Abstract available
    
    
24. CASJENS S, Hovanec J, Glaser N, Massag J, et al
    Occupational risk factors for depression and anxiety symptoms: Insights from a large cohort study during and after the SARS-CoV-2 pandemic.
    PLoS One. 2026;21:e0346871.
    PubMed         Abstract available
    
    
25. JIANG KP, Bennett S, Yager P
    Heat-actuated valve implementation in a point-of-care, paper-based microfluidic device for infectious disease detection.
    PLoS One. 2026;21:e0344750.
    PubMed         Abstract available
    
    
26. ABBAS U, Laghari RN, Ahmed I, Musawwir UA, et al
    Acute SARS-CoV-2 viral load and systemic inflammation are associated with neuropsychiatric and musculoskeletal symptoms in long COVID.
    PLoS One. 2026;21:e0346978.
    PubMed         Abstract available
    
    
27. OZATO N, Hori S, Miyai N, Takase H, et al
    Association of visceral fat and plasmacytoid dendritic cell-derived interferon alpha with SARS-CoV-2 infection.
    PLoS One. 2026;21:e0344870.
    PubMed         Abstract available
    
    
28. DIAS GF, Fan C, Han M, Wang X, et al
    COVID-19 in hemodialysis patients: New insights into metabolomic profile dynamics from 60 days pre- to 60 days post-diagnosis.
    PLoS One. 2026;21:e0346687.
    PubMed         Abstract available
    
    
29. MOHTASHAM F, Hashemi Nazari SS, Pourhoseingholi MA, Kavousi K, et al
    Hybrid feature-selection and diversity-guided stacking framework for interpretable ensemble learning: Application to COVID-19 mortality prediction.
    PLoS One. 2026;21:e0341198.
    PubMed         Abstract available
    
    
30. LEE SJ, Kim J, Han M, Lee JA, et al
    Distinct plasma cytokine and chemokine profiles in severe COVID-19 and septic shock.
    PLoS One. 2026;21:e0347126.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

31. GOLDMAN N, Pebley AR
    The Latino health experience: Past and future.
    Proc Natl Acad Sci U S A. 2026;123:e2530795123.
    PubMed         Abstract available
    
    
32. HUOT M, Wang D, Shakhnovich E, Monasson R, et al
    Constrained evolutionary funnels shape viral immune escape.
    Proc Natl Acad Sci U S A. 2026;123:e2536956123.
    PubMed         Abstract available
    
    
33. FARIAS A, Bridgeman VL, Rodrigues FS, Puttur F, et al
    Type I interferons induced upon respiratory viral infection impair lung metastatic initiation.
    Proc Natl Acad Sci U S A. 2026;123:e2412919123.
    PubMed         Abstract available
    
    

    
    Vaccine

34. HSIEH SM, Choi MJ, Chen YC, Cheng SY, et al
    Cost-effectiveness of vaccination of older adults with an MF59(R)-adjuvanted quadrivalent influenza vaccine compared to standard-dose and high-dose vaccines in South Korea and Taiwan.
    Vaccine. 2026;80:128533.
    PubMed         Abstract available
    
    
35. ANYALECHI EG, Marquez PL, Rubin MN, Johannsen SP, et al
    Safety of seasonal inactivated influenza vaccines in children 6 months-17 years of age in the Vaccine Adverse Events Reporting System (VAERS) 2018-2023: before, during, and after the COVID-19 pandemic public health emergency.
    Vaccine. 2026;81:128569.
    PubMed         Abstract available
    
    

    
    Virology

36. SWIERKOT J, Tyczynska KM, Siemaszko J, Madej M, et al
    The association of selected genetic polymorphisms with adverse events following COVID-19 vaccination: a single-centre prospective observational cohort study.
    Virology. 2026;619:110876.
    PubMed         Abstract available
    
    
37. CHEN G, Liang D, Liu M, Lv Z, et al
    Theaflavins suppresses RSV infection by modulating the MAVS-I-IFN pathway.
    Virology. 2026;619:110872.
    PubMed         Abstract available
    
    
38. LIU R, Patterson L, Yeasmin M, Kim KH, et al
    Low-dose multivalent COVID-19 mRNA vaccines enhance broadly cross-reactive antibodies and protective immune responses of co-administered protein-based vaccines.
    Virology. 2026;619:110884.
    PubMed         Abstract available
    
    
39. WANG Z, Wongnak R, Oba M, Mizutani T, et al
    Omicron RBD expressed in E. coli outperforms mammalian-expressed S1 spike protein in generating highly neutralizing anti-SARS-CoV-2 antibodies in mice.
    Virology. 2026;619:110894.
    PubMed         Abstract available
    
    
40. RICHARDSON SAS, Boodhoo N, Bhat S, Wells J, et al
    Differential outcomes of viral co-infections with high pathogenicity avian influenza A(H5N6) and SARS-CoV-2 in mammalian in vitro systems.
    Virology. 2026;620:110912.
    PubMed         Abstract available
    

#Ocular findings in Northern #Gannets following an #outbreak of high pathogenicity avian #influenza #H5N1

 

Abstract

During 2021-2022, high pathogenicity avian influenza (HPAI) caused mass mortality in wild birds across Europe, with Northern Gannets (Morus bassanus) among the most affected. Following the outbreak, unusual alterations in the species' characteristic pale iris were observed in some individuals. Opportunistically captured gannets on Bass Rock (n=52), selected to represent a range of iris pigmentation, were examined. Slit-lamp biomicroscopy, indirect ophthalmoscopy, rebound tonometry and photography were performed. Iris pigmentation was classified as normal, mottled or black. Eleven birds underwent avian influenza virus (AIV) serology. Histopathology was performed on two eyes. Abnormal iris pigmentation was found in 74% of adult and immature gannets, with 61% affected bilaterally. Additional signs consistent with uveitis were present in 77% of affected birds. Iris pigmentation abnormalities were positively associated with AIV H5 seropositivity (Fishers exact test, P=0.018). Histopathology from affected eyes showed increased melanin deposition and disorganisation, including loss of a distinct anterior layer of melanocytic cells and hypertrophy of melanocytes within the iris stroma. Field conditions limited uniform lighting and concurrent serology. Iris pigmentation changes were associated with prior HPAI exposure and frequently accompanied by signs of uveitis, suggesting iris alterations may indicate past infection and potential chronic sequelae.

Competing Interest Statement

The authors have declared no competing interest.

Source: 

Link: https://www.biorxiv.org/content/10.64898/2026.04.15.718625v1

____

Frequent seasonal #reassortment between high and low path #viruses drives the diversification of #influenza #H5N1

 

Abstract

Since 2021, highly pathogenic (HPAI) H5N1 viruses have spread across the Americas, diversifying via reassortment into new genotypes that have spilled into humans and livestock, raising fears of a new influenza pandemic. Pandemic lineages are typically associated with reassortment, but we currently have limited understanding of where and when reassortment is expected to occur, which limits our ability to assess pandemic risks. Using a dataset of 9,052 full-genome sequences, we show that reassortment and novel genotype formation are associated with seasonal variation in low pathogenicity avian influenza (LPAI) cases and with the spatial and host distributions of viral transmission. We pinpoint ducks, geese, and the Central flyway as frequent sources of new genotypes, and show that reassortment rates vary seasonally, driven by mixing between high- and low-pathogenicity viruses. Cattle spillover genotypes (B3.13 and D1.1) evolved during periods of high reassortment, implicating reassortment as a common occurrence in lineages evolving during particular time periods. Together, these findings reframe reassortment as a predictable ecological process, with direct implications for how surveillance and pandemic risk assessment should be designed.

Competing Interest Statement

The authors have declared no competing interest.

Funder Information Declared

US Centers for Disease Control Insight Net, CDC-RFA-FT-23-0069

Source: 

Link: https://www.biorxiv.org/content/10.64898/2026.04.17.719307v1

____

#Infection of the #bovine mammary #gland by avian #H5N1 subclade 2.3.4.4b #influenza viruses

 

Abstract

The emergence of the panzootic clade of highly pathogenic avian influenza H5N1 (2.3.4.4b) in 2020 marked a major expansion in the host range of influenza A viruses (IAVs), raising concerns about further cross‑species transmission events and zoonotic spillover. Introduction of 2.3.4.4b viruses into U.S. dairy herds has resulted in widespread circulation, accompanied by reduced milk yield, mastitis, and high viral loads in milk. Notably, virus circulation in dairy cattle represents a novel route for mammalian adaptation and transmission that has already led to more than 40 human cases in the U.S. since 2024. Here, we investigated whether avian clade 2.3.4.4b viruses could infect mammary tissue from Aberdeen Angus, Holstein Friesian, and Limousin cattle, three breeds commonly farmed in Europe, the Americas, and Oceania. Using mammary gland explants, we inoculated tissues with attenuated reassortant viruses expressing the haemagglutinin and neuraminidase glycoproteins of three 2.3.4.4b viruses that predated the emergence of H5N1 in US cattle: A/chicken/England/053052/2021 (AIV07), A/chicken/Scotland/054477/2021 (AIV09), and A/chicken/England/085598/2022 (AIV48). Infected epithelial cells were identified using immunohistochemistry in explants from both the teat and gland cistern for all three breeds following infection with AIV09 and AIV48, indicating that mammary tissue from each of the three tested cattle breeds cattle is permissive to H5N1 infection. Lectin staining showed expression of both α2,3‑linked and α2,6‑linked sialic acids in the mammary tissue of all donors showing that all three breeds have the potential to support infection with both avian-adapted and mammalian adapted IAVs. Together, these findings demonstrate that mammary glands from both beef and dairy cattle breeds are permissive to infection with avian‑adapted and mammalian-adapted H5N1 viruses and highlight the potential for this tissue to act as a mixing vessel for IAV reassortment, underscoring the need to include cattle in ongoing H5N1 surveillance and risk‑assessment frameworks.

Competing Interest Statement

The authors have declared no competing interest.

Funder Information Declared

Medical Research Council, https://ror.org/03x94j517, MR/Y03368X/1, MR/Y03368X/1, MC_UU_0034/2, MC_UU_0034/3, MC_UU_0034/1

Biotechnology and Biological Sciences Research Council, https://ror.org/00cwqg982, BB/V004697/1

Source: 

Link: https://www.biorxiv.org/content/10.64898/2026.04.16.718897v1

____

Acquisition of specific #human respiratory tract binding of 2.3.4.4b #H5N1 #hemagglutinins requires multiple #mutations

 

Abstract

It has been suggested that the hemagglutinin of the human-infecting cattle-derived 2.3.4.4b virus A/Texas/34 (H5TX) requires only one mutation, namely Q226L, to switch from binding avian-type to human-type receptor preference. In this study, we examined the binding of H5TX Q226L, along with other key mutations, to sections of human trachea. We conclude that, while H5TX Q226L can bind human-type receptors, more than a single mutation is required for this protein to bind to human respiratory tract tissue. We also report changes in receptor-binding specificity of another 2.3.4.4b HA mutant, H5FR Q226L, associated with the presence of a multibasic cleavage site. This study offers insight into the determinants of evolution towards human-type receptor binding in currently circulating H5Nx viruses. It also emphasizes the importance of testing individual strains using additional methods, including tissue-based approaches, alongside synthetic glycans.

Competing Interest Statement

The authors have declared no competing interest.

Funder Information Declared

NWO, OCENW.M20.106

Horizon, 862605

Source: 

Link: https://www.biorxiv.org/content/10.64898/2026.04.16.718875v1

____

Susceptibility of wild and domestic #songbirds to #Usutu virus

Abstract

Usutu virus (USUV) is an emerging mosquito-borne orthoflavivirus that can cause neuroinvasive disease in humans and wild birds. USUV clusters phylogenetically within the Japanese encephalitis virus serocomplex, sharing antigenic and ecological similarity with West Nile virus (WNV). USUV is maintained in an enzootic cycle primarily involving passerine birds and Culex spp. mosquitoes. USUV was first isolated in South Africa in 1959 and has since spread throughout Africa and Europe, causing mortality and disease in several wild bird populations, specifically the Eurasian blackbird (Turdus merula). To understand transmission and pathogenesis of USUV in birds, we sought to develop passerine bird models of infection using wild-caught house finches (Haemorhous mexicanus), wild-caught American robins (Turdus migratorius), domestic canaries (Serinus canaria domestica), and captive-bred zebra finches (Taeniopygia guttata). Birds were inoculated with one or two isolates of USUV and viremia was measured. House finches, American robins, and canaries were susceptible to USUV, with 100% of inoculated birds developing viremia. These avian species reach viremias that have the potential to infect Cx. quinquefasciatus mosquitoes. Clinical disease and histopathological evidence of disease were severe in American robins and moderate to severe in canaries, with limited disease in house finches. However, zebra finches inoculated with one isolate of USUV did not develop detectable viremia. These findings provide additional tools for studying USUV enzootic transmission and pathogenesis in passerine birds.

Source: 

Link: https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0014213

____

Cross - #protection against highly pathogenic avian #influenza #H5N1 virus from seasonal influenza #vaccines: a systematic review and meta-analysis of #ferret studies

 

ABSTRACT

The recent surge in spillover events of highly pathogenic avian influenza A(H5N1) clade 2.3.4.4b to humans and mammals in North America has raised urgent pandemic concerns. Human H5N1 vaccines are unavailable in most countries. We synthesized data from ferret challenge trials to evaluate whether widely available seasonal influenza vaccines confer cross-protection against lethal H5N1 infection. We systematically searched PubMed, Embase, and Web of Science for ferret studies of lethal H5N1 challenge published up to 5 July 2025 (PROSPERO #CRD42024520346). Random-effects meta-analyses were conducted to compare vaccine efficacy (VE) of seasonal influenza vaccines and H5N1 vaccines against H5N1-related mortality. Seroprotection was defined as a neutralizing antibody titre of ≥1:40. We identified 35 studies (157 trials). Seasonal influenza vaccines without N1 did not confer significant cross-protection (five trials; VE 14.8%, 95% CI –3.6 to 30.0). In contrast, VE was 73% for N1-containing seasonal influenza vaccines (19 trials; 95% CI 54–84) and 77% for H5N1 vaccines overall (133 trials; 95% CI 72–82) (p = 0.52). The VE of N1-containing seasonal influenza vaccines was modestly lower than that of H5N1 vaccines with seroprotection (88%; 66 trials; 95% CI 84–91; p = 0.009), but comparable to H5N1 vaccines that did not achieve seroprotection (63%; 67 trials; 95% CI 52–71; p = 0.29). The VE of seasonal influenza vaccines against H5N1 was robust across sensitivity analyses, with no evidence of publication bias (p = 0.99). Seasonal influenza vaccines significantly reduce H5N1-associated mortality in ferret trials, suggesting the cross-protection potential of currently available vaccines. Human studies are warranted.

Source: 

Link: https://www.tandfonline.com/doi/full/10.1080/22221751.2026.2654278

____

#SARS-CoV-2 #vaccination and #infection elicit cross-neutralizing responses against clade 3 and 4 #sarbecoviruses

 

Abstract

Two sarbecoviruses, SARS-CoV-1 and SARS-CoV-2 that engage ACE2 through their receptor-binding domains, have caused major human outbreaks. The pandemic potential of sarbecoviruses has prompted the discovery and classification of bat and other zoonotic sarbecoviruses that are also able to use human ACE2 or ACE2 ortholog receptors for infection. However, the current human immunological landscape reactive to these SARS-CoV-2-related viruses is not well profiled. Using a panel of pseudotyped lentiviruses expressing only spike proteins, we assess serum neutralization activity against clade 3 and 4 (also designated as clade 1c) receptor binding domain classified sarbecoviruses in a cohort who received a primary series of COVID-19 mRNA vaccines as well as individuals before and after infection with BA.5 or XBB.1.5 variants. Detectable neutralizing responses against clade 3 and 4 sarbecoviruses are observed in both vaccinees and convalescents and are comparable in magnitude to titers against SARS-CoV-2 variants. Infection with XBB.1.5 increases neutralization titers against SARS-CoV-2 variants as well as against clade 3 and 4 sarbecoviruses. Collectively, our findings suggest that the current immunologic landscape of vaccination and infection may confer some level of immunity against a variety of clade 3 and 4 sarbecoviruses, which should inform future pandemic response and pan-sarbecovirus countermeasure efforts.

Source: 

Link: https://www.nature.com/articles/s41467-026-71662-y

____

The virus entry #inhibitor ARN-75039 provides therapeutic #protection against #Lassa virus infection in guinea pigs

 

Abstract

Lassa virus (LASV), a member of the Arenaviridae family, causes Lassa fever. There are no vaccines available for prevention of Lassa fever, and the primary therapeutic for treatment (ribavirin) has questionable antiviral activity and no formal approval for use. Here, we evaluated ARN-75039, an orally bioavailable broad-spectrum mammarenavirus entry inhibitor, against LASV infection in outbred Hartley guinea pigs exposed to a guinea pig–adapted LASV. ARN-75039 was administered for 14 days either 3 or 7 days postexposure (dpe) to LASV. In the first two studies, once-daily dosing at 3 dpe provided protection against lethal infection. A third study with twice-daily dosing at 7 dpe also achieved protection. Both drug regimens offered 100% protection at the lowest tested doses of 3.75 mg/kg (once-daily administration) or 7.5 mg/kg (twice-daily administration). ARN-75039–treated animals exhibited minimal disease signs and undetectable viremia. These results suggest that ARN-75039, for which a phase 1 human clinical trial has now been completed, may offer robust protection against LASV infection.

Source: 

Link: https://www.science.org/doi/10.1126/scitranslmed.adx0938

____

Highly Pathogenic Avian #Influenza #H5N1 Virus #RNA in #Bovine #Semen, #California, #USA, 2024

 

Abstract

Since March 2024, highly pathogenic avian influenza (HPAI) A(H5N1) virus has infected dairy cattle in the United States, prompting concern about novel transmission routes. During an outbreak in California, HPAI H5N1 RNA was detected in an asymptomatic bull’s semen. Although infectious virus was not isolated, semen-associated transmission risks and biosecurity practices remain a concern.

Source: 

Link: https://wwwnc.cdc.gov/eid/article/32/5/25-1639_article

____

#SARS-CoV-2 and #MERS-CoV disrupt #host #protein synthesis via nsp1 with differential effects on the integrated stress response

 

Significance

Coronaviruses cause disease across a wide range of animal species and the human coronaviruses SARS-CoV-2 and MERS-CoV have caused epidemics of severe respiratory illness. Thus, it is imperative to understand how these viruses antagonize host responses and cause lethal disease. We show here that the betacoronavirus nonstructural protein 1 (nsp1) promotes shutdown of host protein synthesis while preserving viral protein synthesis and, in addition, promotes degradation of host mRNAs. However, SARS-CoV-2 and MERS-CoV differ in their ability to manipulate the host integrated stress response, indicating that it is important to understand detailed coronavirus–host interactions and how they differ even between lethal coronaviruses. Such insights will inform the development of antiviral therapeutics to treat and prevent current and future coronavirus outbreaks.

Abstract

Coronaviruses pose a serious threat to public health, driving the need for antiviral therapeutics and vaccines. Therefore, it is paramount to understand how this family of viruses evades cellular antiviral responses and establishes productive infection. The conserved coronavirus nonstructural protein 1 (nsp1) has been shown to inhibit host protein synthesis and, in some coronaviruses, promote host messenger RNA (mRNA) degradation while viral mRNAs are protected. We showed previously that severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces activation of host integrated stress response (ISR) kinases protein kinase R (PKR) and PKR-like endoplasmic reticulum kinase (PERK), which promote phosphorylation of eukaryotic initiation factor 2 (eIF2α) and consequent inhibition of host protein synthesis. In contrast, eIF2α remains unphosphorylated during Middle East respiratory syndrome coronavirus (MERS-CoV) infection. To investigate the interactions of nsp1 and the ISR kinases, we utilized recombinant SARS-CoV-2 and MERS-CoV expressing nsp1 with mutations in each of two conserved domains. Upon infection with SARS-CoV-2 nsp1 mutants, translation was shut down in wildtype (WT) and PKR knockout (KO) cells but rescued in PERK KO cells, likely due to reduced p-eIF2α. In contrast, translation was rescued during infection with the analogous MERS-CoV nsp1 mutants even in WT cells. Moreover, SARS-CoV-2 WT suppressed expression of GADD34, a negative regulator of eIF2α phosphorylation, while SARS-CoV-2 nsp1 mutants induced GADD34. In contrast, MERS-CoV WT induced GADD34. Utilizing single-molecule fluorescence in situ hybridization, we found that SARS-CoV-2 and MERS-CoV nsp1 promote host mRNA degradation during WT, but not nsp1 mutant, infection. Thus, SARS-CoV-2 and MERS-CoV differ in interactions with the ISR and nsp1 control of host protein synthesis.

Source: 

Link: https://www.pnas.org/doi/abs/10.1073/pnas.2536296123?af=R

____

#Vaccine-Elicited #Antibody Responses to #Influenza #H3N2 Subclade K

 

{Summary}

Influenza A(H3N2) subclade K (J.2.4.1) is a genetic branch of H3N2 with 11 mutations in hemagglutinin compared with the A/H3N2/Croatia/10136RV/2023 (H3N2 CR/23) vaccine strain, of which 8 mutations are on the hemagglutinin head surface (...) (...). As of February 2026, influenza A viruses currently represent approximately 96.3% of circulating influenza strains in the US, with H3N2 accounting for 88.4% of influenza isolates and subclade K comprising 91.5% of H3N2 isolates. The rapid expansion of H3N2 subclade K represents a major public health concern. This study reports antibody responses to H3N2 subclade K and other influenza strains before and after influenza vaccination.

(...)

Source: 

Link: https://jamanetwork.com/journals/jama/article-abstract/2846268

____

#Population #immunity to clade 2.3.4.4b #H5N1 is dominated by anti - #neuraminidase #antibodies

 

ABSTRACT

Clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses continue to expand geographically and across mammalian hosts, raising concern about pandemic potential. The degree and specificity of pre-existing immunity in humans are key determinants of this risk. We analyzed hemagglutinin (HA)- and neuraminidase (NA)-specific antibody responses in 300 sera collected from adults in New York City. While HA directed binding antibodies to clade 2.3.4.4b H5 were low and hemagglutination-inhibiting antibodies were absent, we detected widespread binding and functional NA antibodies against N1 neuraminidases from clade 2.3.4.4b H5N1 viruses. Neuraminidase inhibition (NI) titers were highest against North American D1.1 genotype N1 viruses and correlated strongly with neutralizing activity, whereas HA-binding antibodies did not. An additional N-linked glycosylation site, as found in the NA of a human D1.1 isolate from British Columbia, reduced susceptibility to NI antibodies. Antibodies titer to N5 from H5N5 were low to minimal. These findings indicate that population-level immunity to clade 2.3.4.4b H5 viruses is dominated by NA-directed antibodies, with important implications for pandemic risk assessment.

IMPORTANCE

Understanding how pre-existing human immunity shapes susceptibility to emerging influenza viruses is central to pandemic preparedness. Here, we determined that human sera contain widespread, functional antibodies targeting H5N1 neuraminidase, which correlate with virus neutralization, whereas HA-directed responses are limited. We further show that acquisition of an NA glycosylation site reduces antibody inhibition, highlighting a potential pathway for immune evasion. These results identify neuraminidase-specific immunity as a major immunological barrier to severe H5N1 disease in humans and emphasize the need to incorporate NA antigenicity into influenza surveillance, risk assessment, and next-generation vaccine design.

Source: 

Link: https://journals.asm.org/doi/10.1128/mbio.00445-26

____

#Genomic similarity to quantitatively evaluate the #reassortment #potential of #H7N9 with other subtypes of avian #influenza viruses

 

Abstract

Introduction: 

The H7N9 influenza virus poses a significant public health threat due to its potential for reassortment and cross-species transmission. This study aims to systematically evaluate the genomic similarity between H7N9 and other influenza A subtypes to identify strains with high reassortment potential and characterize their spatiotemporal and host distribution patterns.

Methods: 

We analyzed nearly 4,000 H7N9 sequences from GISAID and NCBI, alongside representative sequences of other influenza A subtypes. Open reading frames were extracted, and a genomic similarity index was constructed using Euclidean distance, dot product, and cosine similarity measures, with weights optimized via principal component analysis. The index was applied to quantify inter-subtype similarity and predict reassortment-prone strains.

Results: 

High sequence similarity was observed between H7N9 and cognate subtypes (e.g., H7N3, H15N9), with H7N3 exhibiting the highest similarity index (1.00). Validation using known reassortant strains, such as A/Yixing/805/2022 (H3N2), confirmed that strains with high reassortment potential showed significantly elevated similarity scores across all gene segments (p< 0.001). High-similarity outliers analysis identified 581 spillover events, temporally concentrated during 2014–2017, and spatially clustered in regions like the United States, Europe, and Hong Kong. Host analysis highlighted birds—especially chickens, ducks, and turkeys—as key reservoirs for reassortment.

Discussion: 

The genomic similarity index effectively identifies influenza A subtypes with high reassortment potential, supported by retrospective validation and spatiotemporal congruence with documented outbreaks. The concentration of high-similarity strains in specific hosts and regions underscores the role of ecological factors in viral evolution. These findings provide a predictive framework for monitoring emergent reassortants and inform targeted surveillance strategies.

Source: 

Link: https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2026.1777911/full

____

ONWARD: a #OneHealth, pan - #European multidisciplinary #network advancing #surveillance, #research, clinical management and control of zoonotic #hepeviruses

 

Highlight

• HEV remains the leading cause of acute viral hepatitis in Europe

• Surveillance and diagnostics for HEV are heterogeneous across EU/EEA

• Zoonotic HEV circulates widely in pigs, wildlife and food chains

• Rat HEV expands the zoonotic spectrum and clinical burden in Europe

• ONWARD integrates One Health surveillance, research and capacity building

Abstract

Zoonotic hepeviruses, particularly hepatitis E virus (HEV, species Paslahepevirus balayani) represent a major yet underestimated public health challenge in Europe. Despite being the leading cause of acute viral hepatitis, surveillance, diagnostic practices and prevention strategies remain heterogeneous across EU/EEA countries, limiting comparability and hindering accurate burden estimates. Underdiagnosis is further compounded by extrahepatic manifestations and the growing impact of chronic HEV infection in immunocompromised patients. At the human–animal–environment interface, zoonotic HEV circulates widely in domestic pigs, wildlife and food products, while coordinated surveillance and control measures remain inconsistently implemented. The recent recognition of ratHEV (species Rocahepevirus ratti) as a cause of acute and chronic hepatitis in Europe further expands the spectrum of zoonotic hepevirus infections and underscores the need for integrated One Health approaches. To address these challenges, the One Health Zoonotic Hepevirus Network (ONWARD; COST Action CA24140) was launched in 2025 as a pan-European, multidisciplinary collaboration uniting experts across human, veterinary, food safety and environmental health sectors. ONWARD aims to harmonise diagnostic tools, strengthen clinical research, integrate multisectoral surveillance, promote capacity building and support evidence-based policy development. By fostering coordination with European stakeholders ONWARD provides a structured framework to strengthen preparedness, surveillance and response to zoonotic hepevirus threats across Europe.

Source: 

Link: https://www.sciencedirect.com/science/article/pii/S1386653226000338?dgcid=rss_sd_all

____

Historical #Pandemic and Contemporary #Influenza A Viruses Reveal #PB2 M631L as a Convergent #Adaptation to #Human ANP32

 

Abstract

Understanding the genetic changes that allow avian influenza A viruses (IAVs) to switch their natural hosts and establish productive infection in humans is important for pandemic risk assessment. Adaptations in the IAV polymerase are required to overcome species-specific restrictions imposed by host ANP32 proteins. Notably, avian virus polymerase is generally only poorly supported by human ANP32 proteins due to species-specific differences. Consequently, efficient polymerase adaptation to the binding interface of human ANP32 requires distinct amino acid changes, such as PB2 E627K. A separate adaptation, PB2 M631L, has recently been reported in mammalian-adapted IAV; however, its functional role across divergent viral lineages and its relationship to host ANP32-dependent adaptation remain incompletely defined. Here, we examine PB2 M631L in the polymerases of a 1918 pandemic strain, a recombinant contemporary H1N1pdm09, and a recent clade 2.3.4.4b H5N1 virus. Using polymerase activity and protein-interaction assays, we show that PB2 M631L enhances polymerase activity and ANP32 binding in human—but not avian—contexts, and that this effect is conserved across multiple viral backgrounds. In H1N1pdm09, PB2 M631L also increased virus replication in mammalian cells. These findings indicate that PB2 M631L contributes to enhanced polymerase compatibility with human ANP32 proteins and are consistent with a role in adaptation across multiple influenza virus lineages. Our results highlight how analysis of historical pandemic strains can inform risk assessment for future emerging viruses.

Source: 

Link: https://www.mdpi.com/2076-2607/14/4/859

____

#Coronavirus Disease Research #References (by AMEDEO, April 11 '26)

 

Emerg Infect Dis

1. NILLES EJ, Paulino CT, Vasquez M, Duke W, et al
   Acute Febrile Illness Surveillance for Estimating Population Immunity, Dominican Republic, 2021.
   Emerg Infect Dis. 2026;32.
   PubMed         Abstract available
   
   

   
   Infect Control Hosp Epidemiol

2. LEUCCI AC, Sasdelli E, Caselli L, Fabbri E, et al
   Healthcare-associated infections in Italian long-term care facilities: a machine learning analysis of a 12-month cohort.
   Infect Control Hosp Epidemiol. 2026 Apr 8:1-8. doi: 10.1017/ice.2026.10413.
   PubMed         Abstract available
   
   
3. NG I, Kave B, Paynter C, Bodas C, et al
   Speech intelligibility and hearing acuity assessments of N95/P2 respirator with under-mask elastic band beard cover.
   Infect Control Hosp Epidemiol. 2025;46:1127-1133.
   PubMed         Abstract available
   
   
4. MILNER AL, Eckstein EC, Donskey CJ
   Does one size fit all for contact precautions implementation? Impact of requiring use of gloves and gowns for every room entry on personnel time, personal protective equipment costs, and carbon footprint.
   Infect Control Hosp Epidemiol. 2025;46:1161-1163.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

5. CHOI Y, Bae GH, Jeon J, Yoon J, et al
   Short-Term Mortality and the Impact of Disability Type Following COVID-19 Among Individuals with Disabilities: A Population-Based Study.
   Int J Infect Dis. 2026 Apr 4:108677. doi: 10.1016/j.ijid.2026.108677.
   PubMed         Abstract available
   
   
6. OGAWA K, Xu YS, Shimakawa Y, Chowell G, et al
   Secondary SARS-CoV-2 Transmission from Childcare Workers versus Teachers in School-Associated Screening Events, Okinawa, Japan, January-March 2022.
   Int J Infect Dis. 2026 Apr 2:108672. doi: 10.1016/j.ijid.2026.108672.
   PubMed         Abstract available
   
   
7. UNSELD M, Sturtzel B, Meyer AL, Blaise M, et al
   Real-world effectiveness and antibody responses of BNT162b2 vaccination in long-term care residents: a retrospective case-control study.
   Int J Infect Dis. 2026 Apr 2:108682. doi: 10.1016/j.ijid.2026.108682.
   PubMed         Abstract available
   
   
8. PETERSEN E, Hviid AP
   Inosine pranobex as a treatment of SARS-CoV2?
   Int J Infect Dis. 2026 Dec 31:108657. doi: 10.1016/j.ijid.2026.108657.
   PubMed        
   
   

   
   Intensive Care Med

9. GODOLPHIN PJ, Fisher DJ, Bradbury CA, Murthy S, et al
   Intermediate- versus prophylactic-dose heparin for hospitalised patients with COVID-19: an updated meta-analysis of randomised trials.
   Intensive Care Med. 2026 Apr 7. doi: 10.1007/s00134-025-08128.
   PubMed        
   
   

   
   J Infect

10. LOMHOLT FK, Valentiner-Branth P, Nielsen RT, Slotved HC, et al
    A real-time register-based surveillance system for non-invasive and invasive pneumococcal disease.
    J Infect. 2026 Apr 4:106744. doi: 10.1016/j.jinf.2026.106744.
    PubMed         Abstract available
    
    

    
    J Virol

11. JEFFERSON V, Endlich-Frazier A, Letko M
    Exploring coronavirus cell entry with functional viromics.
    J Virol. 2026 Apr 6:e0172825. doi: 10.1128/jvi.01728.
    PubMed         Abstract available
    
    
12. CHEN N, Kleine-Weber H, Alkharsah K, Winkler M, et al
    Q1020R in the spike proteins of MERS-CoV from Arabian camels confers resistance against soluble human DPP4.
    J Virol. 2026 Apr 6:e0028226. doi: 10.1128/jvi.00282.
    PubMed         Abstract available
    
    

    
    Life Sci

13. CHEN W, Ji MC, Jung E, Shin JS, et al
    Broad-spectrum coronavirus inhibition by RSV fusion inhibitors targeting six-helix bundle formation.
    Life Sci. 2026 Mar 31:124357. doi: 10.1016/j.lfs.2026.124357.
    PubMed         Abstract available
    
    

    
    Science

14. PHILLIPS KA, Horn DM, Califf RM
    Diagnostics investments and disease burden.
    Science. 2026;392:151-153.
    PubMed         Abstract available
    
    
15. KHAN S, Zhang R, Khan A, Shah A, et al
    We survived COVID-19-Are we ready for Nipah?
    Science. 2026;392:157-158.
    PubMed        

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, April 11 '26)

 

Biochemistry

1. VOGET R, Gutschow M
   Early Kinetic Characterization of SARS-CoV-2 Main Protease Inhibitors: A Review and Guidance for Biochemical Assessments.
   Biochemistry. 2026;65:860-881.
   PubMed         Abstract available
   
   

   
   Epidemiol Infect

2. MILLER AC, Boonstra DE, Cavanaugh JE, Boikos C, et al
   Disease burden associated with influenza activity at the population level.
   Epidemiol Infect. 2026 Apr 6:1-28. doi: 10.1017/S0950268826101320.
   PubMed        
   
   
3. ABUNIJELA S, Greiner T, Haas W, Kerber R, et al
   Frequency, dynamics, and duration of faecal shedding in SARS-CoV-2-infected individuals, a scoping review.
   Epidemiol Infect. 2026;154:e44.
   PubMed         Abstract available
   
   

   
   J Exp Med

4. MATHEW NR, Gailleton R, Scharf L, Schon K, et al
   Nasal CD4+ tissue-resident memory T cells provide cross-protective immunity to influenza.
   J Exp Med. 2026;223:e20251793.
   PubMed         Abstract available
   
   

   
   J Infect Dis

5. ULANOWICZ CJ, Alarcon PC, Damen MSMA, Wayland JL, et al
   Distinct inflammatory programming of thoracic cavity white adipose immune cells regulates influenza pathogenesis.
   J Infect Dis. 2026 Apr 7:jiag201. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   N Engl J Med

6. PARDO-SECO J, Martinon-Torres F
   High-Dose Influenza Vaccine and Hospitalizations in Older Adults. Reply.
   N Engl J Med. 2026;394:1454.
   PubMed        
   
   
7. JOHANSEN ND, Biering-Sorensen T
   High-Dose Influenza Vaccine and Hospitalizations in Older Adults. Reply.
   N Engl J Med. 2026;394:1454.
   PubMed        
   
   
8. KANEDA Y, Fujikawa T
   High-Dose Influenza Vaccine and Hospitalizations in Older Adults.
   N Engl J Med. 2026;394:1453-1454.
   PubMed        
   
   
9. CHEN HY, Liao JC, Yong SB
   High-Dose Influenza Vaccine and Hospitalizations in Older Adults.
   N Engl J Med. 2026;394:1453.
   PubMed        
   
   

   
   Pediatrics

10. OLSON SM, Ahmad HM, Wielgosz K, Michaels MG, et al
    Pediatric Vaccine Effectiveness Against Influenza Hospitalization And Outpatient Visits: 2021-2024.
    Pediatrics. 2026 Apr 6:e2025073973. doi: 10.1542/peds.2025-073973.
    PubMed         Abstract available
    
    
11. LUCACCIONI H, Maurel M, Perez-Gimeno G, Buda S, et al
    Influenza Vaccine Effectiveness in European Primary Care Pediatric Practices: 2022-2024.
    Pediatrics. 2026 Apr 6:e2025072907. doi: 10.1542/peds.2025-072907.
    PubMed         Abstract available
    
    

    
    PLoS One

12. ANTAO V, Krueger P, Meaney C, Kwong JC, et al
    Predictors of burnout among academic family medicine faculty: Looking back to plan forward.
    PLoS One. 2026;21:e0344702.
    PubMed         Abstract available
    
    
13. SPINOS D, Beech T, Lee J, Coulson C, et al
    Referral to treatment times in the National Health Service of England: A five-year analysis of the impact of the COVID-19 Pandemic and socioeconomic deprivation and future implications for Ear, Nose and Throat service delivery.
    PLoS One. 2026;21:e0346596.
    PubMed         Abstract available
    
    
14. SHARBAYTA SS, Jo Y, Jung J, Buonomo B, et al
    The impact of human behavioral adaptation stratified by immune status on COVID-19 spread with application to South Korea.
    PLoS One. 2026;21:e0345642.
    PubMed         Abstract available
    
    
15. GRAFF I, Berger M, Schmid M, Kogej M, et al
    A decade of triage with the Manchester Triage System-The MTS big data study.
    PLoS One. 2026;21:e0344598.
    PubMed         Abstract available
    
    
16. FELLER RL, Narraway CL, Burslem DF, Colucci-Gray L, et al
    Private garden uses and associated mental well-being benefits during the first UK Covid-19 lockdown - a social media investigation.
    PLoS One. 2026;21:e0289446.
    PubMed         Abstract available
    
    
17. PAN C, Shen W
    Revisiting price linkages between London and Shanghai base metal futures markets: A time-frequency connectedness analysis.
    PLoS One. 2026;21:e0346602.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

18. HA J, Sharma P, Ta S, Tsukuda S, et al
    Hypoxia inducible factors regulate pneumovirus replication by enhancing innate immune sensing.
    Proc Natl Acad Sci U S A. 2026;123:e2506647123.
    PubMed         Abstract available
    
    
19. PARENTI NA, Cusic R, Renner DM, Jackson N, et al
    SARS-CoV-2 and MERS-CoV disrupt host protein synthesis via nsp1 with differential effects on the integrated stress response.
    Proc Natl Acad Sci U S A. 2026;123:e2536296123.
    PubMed         Abstract available
    
    

    
    Vaccine

20. MCCULLOUGH R, Reid A, Smyth D, O'Neill MT, et al
    Leadership matters: ward manager vaccination status influences nursing staff influenza vaccine uptake.
    Vaccine. 2026;80:128541.
    PubMed         Abstract available
    
    
21. ZHANG J, Gong C, Xu Z, Han R, et al
    Multi-mode spatial accessibility to vaccination services and its impact on influenza-related hospitalisations among older adults.
    Vaccine. 2026;80:128540.
    PubMed         Abstract available
    
    

    
    Virus Res

22. WU Y, Sun W, Xia Y, Feng Y, et al
    The influenza B virus candidate vaccine expressing H3 hemagglutinin developed in suspension MDCK cells confers protection against lethal H3N2 avian influenza in BALB/c mice.
    Virus Res. 2026;367:199722.
    PubMed         Abstract available